Want to see FR:ALDVI full AI Analyst Report?
ALDVI Stock Chart & Stats
€0.92
-€0.05(-2.91%)
At close: 4:00 PM EDT
€0.92
-€0.05(-2.91%)
Day’s Range― - ―
52-Week Range€0.66 - €2.35
Previous CloseN/A
Volume71.90K
Average Volume (3M)128.93K
Market Cap
€12.61M
Enterprise Value€38.08
Total Cash (Recent Filing)€1.34M
Total Debt (Recent Filing)€19.00M
Price to Earnings (P/E)290.6
Beta0.12
Next Earnings
Apr 01, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.72
Shares Outstanding14,609,619
10 Day Avg. Volume83,592
30 Day Avg. Volume128,930
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)-0.87
Price to Sales (P/S)3.81
P/FCF Ratio-5.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.47
Revenue Forecast (FY)€6.60M
Bulls Say, Bears Say
Bulls Say
Rare-disease SpecializationFocus on rare kidney and metabolic diseases gives Advicenne a defined specialty position, with Sibnayal addressing dRTA and other modified-release products extending its therapeutic capabilities. This specialization can support focused development and commercialization over the medium term.
Commercialized Product PortfolioAdvicenne combines direct or partnered sales of marketed medicines with licensing and commercialization arrangements. This model can broaden geographic reach and create multiple revenue channels, while allowing partners to support distribution and market access in selected territories.
Improving Gross MarginThe return to positive gross margin in 2025 indicates that product economics improved at the gross-profit level. Although this has not yet produced sustainable net profitability, better gross profitability could provide a foundation for improved operating leverage if revenue scales.
Bears Say
Negative EquityPersistent negative equity signals a fragile capital structure and materially reduces financial flexibility. Combined with sizable debt relative to assets, it may constrain investment choices and leave Advicenne more exposed when additional funding is required to sustain operations.
Persistent Cash BurnRecurring negative operating and free cash flow show that the business is not yet self-funding. The renewed deterioration in 2025 increases the need for external financing, which can limit strategic flexibility and make continued commercialization dependent on securing capital.
Weak And Volatile ProfitabilitySmall, volatile revenue and continuing operating and net losses indicate that the current commercial base has not reached sufficient scale. Negative growth in 2025 adds execution pressure, while persistent losses weaken the prospect of near-term internally funded expansion.
Advicenne SA News
ALDVI FAQ
What was Advicenne SA’s price range in the past 12 months?
Advicenne SA lowest stock price was €0.66 and its highest was €2.35 in the past 12 months.
What is Advicenne SA’s market cap?
Advicenne SA’s market cap is €12.61M.
When is Advicenne SA’s upcoming earnings report date?
Advicenne SA’s upcoming earnings report date is Apr 01, 2027 which is in 193 days.
How were Advicenne SA’s earnings last quarter?
Advicenne SA released its earnings results on Sep 17, 2026. The company reported €0.32 earnings per share for the quarter.
Is Advicenne SA overvalued?
According to Wall Street analysts Advicenne SA’s price is currently Overvalued.
Does Advicenne SA pay dividends?
Advicenne SA does not currently pay dividends.
What is Advicenne SA’s EPS estimate?
Advicenne SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Advicenne SA have?
Advicenne SA has 14,609,619 shares outstanding.
What happened to Advicenne SA’s price movement after its last earnings report?
Advicenne SA reported an EPS of €0.32 in its last earnings report. Following the earnings report the stock price went up 10.13%.
Which hedge fund is a major shareholder of Advicenne SA?
Currently, no hedge funds are holding shares in FR:ALDVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Advicenne SA
Advicenne S.A. operates as a specialized pharmaceutical firm, focusing on the innovation and commercialization of therapeutic solutions for various kidney-related disorders. The company's primary offering, Sibnayal, targets both distal renal tubular acidosis and cystinuria. Established in 2007, Advicenne S.A. maintains its principal offices in Paris, France.